Predicting response to Anti-TNF Agents for the treatment of crohn's disease. - Test2 - elhamkhani - TriplyDB

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

http://www.wikidata.org/entity/Q34408990

about

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease Therapeutic drug monitoring in inflammatory bowel disease Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies.Predictors of aggressive inflammatory bowel disease.Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents.Second Korean guidelines for the management of Crohn's disease.Management of Crohn's disease in poor responders to adalimumab.Personalizing therapy for inflammatory bowel diseases.Targeting TNF-α for the treatment of inflammatory bowel disease.Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis.Optimizing biological therapy in Crohn's disease.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease Clinical Decision Support Tools: The Evolution of a Revolution.Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Biomarkers in Search of Precision Medicine in IBD.Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140 Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.Inflammatory bowel disease: towards a personalized medicine.Predicting and explaining inflammation in Crohn's disease patients using predictive analytics methods and electronic medical record data.Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab.

P2860

Q26745721-49C2365C-40E9-4EAA-904D-C7FC1F65DA87 Q26852729-38A9CBC3-C43D-4397-8C94-F764506CD782 Q26994776-A7D23504-EBFB-407B-96E0-549C56FC4EEA Q28072105-60B474AD-10E6-4D86-B6A9-D9D40CFEBEE4 Q28651176-984EE33D-18EF-4AC6-9486-4BB4E9777807 Q35627602-38596C18-AAFA-40AE-BA48-4F9374F6B894 Q35691407-2AF60C22-5105-4C5B-94D1-93064F3C934E Q37306556-4BB3EE57-B9A4-4AE6-AC0A-99D10796E92D Q37662498-B0833CF3-1AA7-4B4F-97DC-2D6CC3FED3C6 Q37708656-09FC9DED-F4F6-4265-B4C7-AB859D220178 Q38132279-29FC2DD2-187C-49EC-BB22-674EE8B79CE2 Q38160905-808C1FEC-CAEC-4EEB-89D8-F3B30AE4B939 Q38240881-35288760-AE64-43A0-9470-AB7C51C74A5B Q38608158-E359766B-EF3B-4E64-A6A6-BA9305465660 Q38619950-9B5B0B5C-2BB4-4490-A887-97318D5A5942 Q38660544-1352BBDE-719F-411F-BD59-73BD9C4BD148 Q38702792-DDE12EB0-316D-4505-9773-6BC6718D24ED Q38791894-AB6A8E8D-F4A2-4963-9F59-FC805F268E4E Q38822920-6C11194F-E2C5-4654-A243-AD8A64EA62E6 Q38850063-A275E2C5-FCEF-4B48-B5F7-7EA5E7E7CA8B Q38964878-E33DC4BE-030D-4689-B933-05B8823980EC Q38990031-90189366-C2EB-41F5-8DBD-CA73B1CDE34B Q39116859-889D94CC-7146-4BA6-8B89-AEF68407C436 Q39841706-D4C0FA68-A8DA-4939-9F07-8A61C5F00FA2 Q40594199-9106CE1C-8906-4DBA-AFCB-5278AE6B260C Q41122444-418991BB-29C6-4431-BA8C-722AB14BADBF Q41321344-F71331F4-6B3E-4426-A066-5C427CCD0A0A Q46003614-5A8A154D-1113-40C0-87F3-EFD37D379338 Q47159585-FC14E3BD-B61A-43A1-A93E-16C5CB22DDC2 Q47805665-FBB722AF-D55D-4729-B564-83F728F5124B Q48327816-2258C7A3-BC47-4E1C-9F07-A797681ED42C Q49570157-E8AAB0D5-6A62-4E54-8388-E16927118423 Q50102743-825DF113-F95B-4BA3-8163-07548FBF1632 Q50496500-E02E00BD-8D71-4945-9F42-C9A956FA27A2

P2860

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

http://www.wikidata.org/entity/Q34408990

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@ast

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@en

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@nl

type

label

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@ast

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@en

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@nl

prefLabel

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@ast

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@en

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@nl

P1433

Q34408990-3DC395F6-05F2-4B3A-9D81-DF2B5C5D585F

P1476

Q34408990-A6D4DAF3-D365-4D14-85DF-12FD98D6CA50

P2093

Q34408990-6D869F47-42E7-42EF-8EB8-54C5CEA61C4A

Q34408990-BC2735EC-6228-4A71-BDC6-394986F4F4CD

P2860

Q34408990-020741EA-850C-42F0-9ADB-C5EA49040E1E

Q34408990-05475654-25BE-4466-B8CE-FD2C718C2C99

Q34408990-08F2A91C-7EF2-47A0-AB44-D626AB407419

Q34408990-13961251-07A3-4306-8F2E-00D48DA8C136

Q34408990-1C0AF5BA-B44A-4DA1-80E4-674395564FD9

Q34408990-22E4CEF5-1F47-4C02-941C-33790B8D4E66

Q34408990-43F62008-69EC-46AE-865C-DD6639B23351

Q34408990-4C30A623-3F26-42EA-BCC0-71136F5BCA4A

Q34408990-4FA8DEB0-B421-4DFC-B431-4AC8FDFF0E55

Q34408990-535E77D7-ED29-4FEE-9841-57717E3AFEFE

P304

Q34408990-7A8FB343-A01A-4E3E-8608-2173E9DDC775

P31

Q34408990-685c726f-1c5a-4344-a78a-5e7f2964f662

Q34408990-75B86D83-F3A9-4BD0-9F3A-B248F6E371A8

P356

Q34408990-2F7749F2-4FA7-4F0D-BF48-D6405248B68D

P433

Q34408990-BED1307D-67D9-49B6-ABD6-6AB4F122CAB4

P478

Q34408990-666B0D7D-BC13-446C-95B5-A1FD8FA9AB6F

P577

Q34408990-BE1EFBB2-D9F0-49C4-9A96-671D263579CB

P698

Q34408990-6F481A5C-1FDE-4E75-8511-427B0A1CC381

P921

Q34408990-702A05A7-D50D-413A-9635-0D9B36DEEBEF

Q34408990-76469FE9-A2C6-4256-BBBC-A51D0807321E

Q34408990-93BC260A-F119-48B6-8553-5FBECD4AD324

P932

Q34408990-AC212A20-D2A5-4B1B-8ACE-CBCAD1F2D917

P356

1756283X09336364

P1433

Therapeutic Advances in Gastroenterology

P1476

Predicting response to Anti-TNF Agents for the treatment of crohn's disease.

@en

P2093

Corey A Siegel

http://www.w3.org/2001/XMLSchema#string

Gil Y Melmed

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Risks and benefits of infliximab for the treatment of Crohn's disease

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

Prediction of response to infliximab in Crohn's disease.

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.

Predictors of response to infliximab in patients with Crohn's disease.

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease.

P304

245-251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X09336364

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21180547

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

3002521

http://www.w3.org/2001/XMLSchema#string